Intra-Cellular Therapies, Inc.

( )
ITCI After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -6.60%123.470.0%$1121.14m
OCGNOcugen, Inc. -1.26%8.630.0%$797.67m
AMGNAmgen, Inc. 0.04%227.811.3%$546.41m
REGNRegeneron Pharmaceuticals, Inc. 0.35%463.192.7%$534.62m
NVAXNovavax, Inc. -9.71%157.8792.9%$533.68m
GILDGilead Sciences, Inc. 0.20%64.751.0%$502.19m
ILMNIllumina, Inc. -3.82%383.623.5%$481.24m
VRTXVertex Pharmaceuticals, Inc. 0.76%213.581.9%$461.68m
ALXNAlexion Pharmaceuticals, Inc. -0.03%150.062.0%$329.21m
BNGOBioNano Genomics, Inc. 8.67%7.770.0%$322.31m
CRSPCRISPR Therapeutics AG -0.90%113.620.6%$321.43m
BIIBBiogen, Inc. -0.26%270.011.7%$296.77m
EXASEXACT Sciences Corp. -4.17%116.5718.4%$244.18m
SGENSeagen Inc. -0.45%148.685.8%$208.59m
PACBPacific Biosciences of California, Inc. -6.49%27.377.2%$176.05m

Company Profile

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.